Belépés

NCT07758010Toboroz

One-Day cTBS Over the Precuneus

One-Day cTBS Over the Precuneus (OcTOPUS)

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. szept. 11.

Rövid összefoglaló (regiszter, angolul)

The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression. Treatment-resistant depression is depression that has not improved enough after at least two adequate antidepressant medication treatments. TMS is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain. The main questions this study aims to answer are: * Does continuous theta-burst stimulation (cTBS) targeting the precuneus reduce depressive symptoms 4 weeks after treatment compared with sham stimulation? * Does intermittent theta-burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex reduce depressive symptoms 4 weeks after treatment compared with sham stimulation? Researchers will compare precuneus cTBS, left dorsolateral prefrontal cortex iTBS, and sham stimulation to determine whether either active treatment reduces depressive symptoms more than sham stimulation. Participants will be randomly assigned to one of the three groups and will not be told which treatment they initially receive. Participants will: * Complete screening procedures and baseline assessments of depression, rumination, and cognitive function * Receive 20 sessions of active or sham TMS during one in-person study day * Complete follow-up assessments 1, 2, 3, and 4 weeks after the intervention * Report any side effects or medical problems experienced during the study Participants initially assigned to sham stimulation may choose to receive active TMS after completing the 4-week follow-up period. Those who choose this option will receive either precuneus cTBS or left dorsolateral prefrontal cortex iTBS and will complete additional follow-up assessments.

Állapot (regiszter)
Toboroz
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
69 (tervezett)
Első benyújtás
2026. aug. 6.
Kezdés
2026. szept. 8.
Elsődleges befejezés
2027. jún. 30.
Fő szponzor
Mclean Hospital
Betegségek
Depresszió
NCT-szám
NCT07758010

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 69
  • 2026. szept. 8. és az elsődleges befejezés (2027. jún. 30.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Metal in the head outside the mouth, such as shrapnel, surgical clips, or metal fragments.
  • Current recreational drug use.

Más betegség

  • Any condition identified through TMS safety screening that, in the judgment of a study physician, presents an unacceptable safety risk for TMS. Such conditions may include:
  • A history of a serious adverse reaction during TMS treatment.
  • A history of seizure.
  • A history of stroke.
  • A history of serious head injury or neurosurgery.
  • An implanted device, such as a cardiac pacemaker, cochlear implant, medical pump, or intracardiac line.
  • Another brain-related condition or an illness that caused brain injury.
  • A family history of epilepsy.
  • Use of a medication or combination of medications, a recent medication change, or medication withdrawal that, in the judgment of a study physician, presents an unacceptable safety risk, including a clinically significant increase in seizure risk.
  • Current or lifetime diagnosis of bipolar I disorder, bipolar II disorder, a schizophrenia spectrum disorder, or another primary psychotic disorder.

Egyéb

  • Frequent or severe headaches.
  • Permanent tattoos on the head or neck.
  • Current pregnancy or possible pregnancy.
  • Active suicidal ideation with intent or plan requiring immediate clinical intervention, or another acute safety concern that cannot be safely managed within the study.

Kiket keres a vizsgálat

  • Age 18 years or older.
  • Able to speak, read, and understand English sufficiently to complete the study assessments and provide informed consent independently.
  • Diagnosis of major depressive disorder according to DSM-5-TR criteria, confirmed by a qualified physician.
  • Treatment-resistant depression, defined as an inadequate response to at least two adequate trials of antidepressant pharmacotherapy.
  • Patient Health Questionnaire-9 (PHQ-9) total score of 10 or higher.

Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
McLean Hospital
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
BelmontEgyesült ÁllamokToboroz

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.